Illumina has completed its acquisition of proteomics company SomaLogic, expanding its multiomics portfolio.
Proteomics is the large-scale study of proteins and how they function in the body. Analysing proteins in biological samples can reveal disease processes that genomics, the study of DNA, may not show on its own.
Multiomics combines several biological approaches, such as DNA and protein analysis, to provide a broader understanding of human health.
Illumina acquired SomaLogic and certain related assets from Standard BioTools for US$350m in cash, plus up to US$75m in near-term performance-based milestones and royalties.
The companies have worked together since late 2021, when they agreed to bring the SomaScan proteomics assay onto Illumina’s high-throughput next-generation sequencing platforms.
SomaLogic’s technology provides insight into protein function, interactions and modifications, helping researchers better understand complex biological systems.
Customers will be able to use technologies including SomaScan, Illumina Protein Prep, SomaSignal Tests, DRAGEN software and Illumina Connected Multiomics to generate large multiomic datasets.
Illumina said the acquisition expands access to SomaLogic’s technologies and services while strengthening its position in the growing proteomics market.
The company added that it will continue supporting SomaLogic customers and partnerships, including service providers using SomaLogic’s array-based readout technology.
Jacob Thaysen, chief executive officer of Illumina, said:
“Welcoming the SomaLogic team to Illumina is an important milestone in executing the multiomics strategy we outlined in 2024. By combining SomaLogic’s highly differentiated proteomics technology with Illumina’s industry-leading innovation and global reach, we are strengthening our ability to deliver scalable insights across genomics and proteomics, helping customers unlock more from every sample in support of better outcomes for patients.”
The acquisition was funded with cash on hand.
Illumina said it will discuss the financial implications of the transaction during its earnings call scheduled for 5 February 2026.
